Wednesday, June 10, 2026

Patent intelligence · US

US 2010280048

Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

granted A61K 31/ 497 A IA61P 9/ 10 A IA61P 9/ 12 A IA61P 11/ 00 A I
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 4
Applicant portfolio 25
Patent details — US 2010280048
Jurisdiction
US
Status
granted
Grant date
Nov 4, 2010
Expiration
Oct 30, 2030
CPC classes
A61K 31/ 497 A I, A61P 9/ 10 A I, A61P 9/ 12 A I, A61P 11/ 00 A I
View on Google Patents ↗

Quick answer

US 2010280048 (Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase) is held by ASTRAZENECA R & D [SE]. Status: granted. Granted Nov 4, 2010. Expires Oct 30, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 497 A I, A61P 9/ 10 A I, A61P 9/ 12 A I, A61P 11/ 00 A I, A61P 11/ 06 A I, A61P 17/ 06 A I

More from ASTRAZENECA R & D [SE]

Related pharmaceutical patents in our USPTO index.

  1. IL 240179

    Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject

    BIOWA INC [US] · Expires Dec 26, 2038

    granted
  2. ZA 201308176

    THERAPEUTIC TREATMENT

    ASTRAZENECA AB [SE] · Expires Dec 18, 2035

    granted
  3. SI 2158199

    PIPERIDINE COMPOUNDS AND USES THEREOF

    ASTRAZENECA AB [SE] · Expires Feb 23, 2031

    granted
  4. DO P2009000148

    DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES

    BAYER SCHERING PHARMA AG [DE] · Expires Oct 10, 2030

    granted
  5. EP 2086964

    BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN

    ASTRAZENECA AB [SE] · Expires Aug 7, 2029

    granted
  6. EP 2079730

    MGLUR5-MODULATOREN

    ASTRAZENECA AB [SE] · Expires Jul 17, 2029

    granted
  7. EP 2064340

    VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN

    ASTRAZENECA AB [SE] · Expires May 29, 2029

    granted

Frequently asked questions

What is US patent 2010280048?

US 2010280048 (Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase) is held by ASTRAZENECA R & D [SE]. Status: granted. Granted Nov 4, 2010. Expires Oct 30, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2010280048?

ASTRAZENECA R & D [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2010280048 expire?

Our index shows an expiration date of Oct 30, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.